Jonathan Kay

Summary

Publications

  1. ncbi Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Jonathan Kay
    From the Division of Rheumatology, Department of Medicine, UMass Memorial Medical Center, and University of Massachusetts Medical School, Worcester, Massachusetts Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, Texas Janssen Research and Development LLC, Spring House University of Pennsylvania, Philadelphia, Pennsylvania, USA Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada Rheumatology, Rheumazentrum Ruhrgebeit, Herne, Germany
    J Rheumatol 43:2120-2130. 2016
  2. pmc Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
    Jonathan Kay
    Division of Rheumatology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, USA
    Core Evid 4:159-70. 2010
  3. doi ACR/EULAR 2010 rheumatoid arthritis classification criteria
    Jonathan Kay
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Rheumatology (Oxford) 51:vi5-9. 2012
  4. doi Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012
    Jonathan Kay
    UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Biologicals 40:517-27. 2012
  5. pmc Biosimilars: a regulatory perspective from America
    Jonathan Kay
    UMass Memorial Medical Center, Rheumatology Center, Memorial Campus, 119 Belmont Street, Worcester, MA 01605, USA
    Arthritis Res Ther 13:112. 2011
  6. doi A rheumatology-specific informatics-based application with a disease activity calculator
    Deborah S Collier
    Massachusetts General Hospital, Boston, MA, USA
    Arthritis Rheum 61:488-94. 2009
  7. pmc Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
    Jonathan Kay
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USA
    Ann Rheum Dis 74:538-46. 2015
  8. doi E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy
    Sudha Visvanathan
    Centocor Research and Development, Inc, Malvern, Pennsylvania, USA
    J Rheumatol 36:1371-9. 2009
  9. doi Evolution of treatment for rheumatoid arthritis
    Katherine S Upchurch
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01605, USA
    Rheumatology (Oxford) 51:vi28-36. 2012
  10. doi Assessment of control of rheumatoid arthritis disease activity
    Karen I Salomon-Escoto
    University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, USA
    Best Pract Res Clin Rheumatol 25:497-507. 2011

Collaborators

Detail Information

Publications18

  1. ncbi Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Jonathan Kay
    From the Division of Rheumatology, Department of Medicine, UMass Memorial Medical Center, and University of Massachusetts Medical School, Worcester, Massachusetts Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, Texas Janssen Research and Development LLC, Spring House University of Pennsylvania, Philadelphia, Pennsylvania, USA Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada Rheumatology, Rheumazentrum Ruhrgebeit, Herne, Germany
    J Rheumatol 43:2120-2130. 2016
    ..Assess 5-year golimumab (GOL) safety in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS)...
  2. pmc Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
    Jonathan Kay
    Division of Rheumatology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, USA
    Core Evid 4:159-70. 2010
    ..However, golimumab has the potential advantage of once monthly subcutaneous administration and the possibility of both subcutaneous and intravenous administration...
  3. doi ACR/EULAR 2010 rheumatoid arthritis classification criteria
    Jonathan Kay
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Rheumatology (Oxford) 51:vi5-9. 2012
    ....
  4. doi Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012
    Jonathan Kay
    UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Biologicals 40:517-27. 2012
    ....
  5. pmc Biosimilars: a regulatory perspective from America
    Jonathan Kay
    UMass Memorial Medical Center, Rheumatology Center, Memorial Campus, 119 Belmont Street, Worcester, MA 01605, USA
    Arthritis Res Ther 13:112. 2011
    ..This paper reviews the processes for approval of biosimilars in the US and the European Union and highlights recent changes in federal regulations governing the approval of biosimilars in the US...
  6. doi A rheumatology-specific informatics-based application with a disease activity calculator
    Deborah S Collier
    Massachusetts General Hospital, Boston, MA, USA
    Arthritis Rheum 61:488-94. 2009
    ..To design a rheumatology-specific tool with a disease activity calculator integrated into the electronic medical records (EMRs) at our institution and assess physicians' attitudes toward the use of this tool...
  7. pmc Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
    Jonathan Kay
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USA
    Ann Rheum Dis 74:538-46. 2015
    ..To assess pooled golimumab safety up to year 3 of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) trials...
  8. doi E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy
    Sudha Visvanathan
    Centocor Research and Development, Inc, Malvern, Pennsylvania, USA
    J Rheumatol 36:1371-9. 2009
    ....
  9. doi Evolution of treatment for rheumatoid arthritis
    Katherine S Upchurch
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01605, USA
    Rheumatology (Oxford) 51:vi28-36. 2012
    ..Current therapy for RA is such that progression from symptom onset to significant disability is now no longer inevitable, and RA patients can anticipate comfortable and productive lives on medical therapy...
  10. doi Assessment of control of rheumatoid arthritis disease activity
    Karen I Salomon-Escoto
    University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, USA
    Best Pract Res Clin Rheumatol 25:497-507. 2011
    ..Because no single measure of RA disease activity fully quantifies the global burden of disease, rheumatologists must follow multiple parameters to assess disease activity thoroughly and to adjust treatment optimally...
  11. pmc Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention
    Sougata Karmakar
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, UMass Memorial Medical Center, Lazare Research Building, Suite 223, 364 Plantation Street, Worcester, MA 01605, USA
    Rheum Dis Clin North Am 36:385-404. 2010
    ..In this review, the authors discuss the current understanding of pathogenic mechanisms of bone erosion in RA and examine current therapeutic approaches to prevent this damage...
  12. doi Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator
    Deborah S Collier
    Massachusetts General Hospital, Boston, MA, USA
    Arthritis Rheum 61:495-500. 2009
    ..To assess physicians' concordance with Disease Activity Score in 28 joints (DAS28) categories calculated by an electronic medical record (EMR)-embedded disease activity calculator, as well as attitudes toward this application...
  13. doi Rheumatic manifestations of diabetes mellitus
    Dorota Lebiedz-Odrobina
    Rheumatology Division, Department of Medicine, University of Massachusetts School of Medicine, 55 Lake Avenue North, Worcester, MA 01655, USA
    Rheum Dis Clin North Am 36:681-99. 2010
    ..Identification of such molecular targets for therapy would promote the development of additional treatments for these and other rheumatic diseases...
  14. doi Relapsing polychondritis
    Ratnesh Chopra
    Rheumatology Center, Memorial Campus, UMass Memorial Medical Center, 119 Belmont Street, Worcester, MA 01605, USA
    Rheum Dis Clin North Am 39:263-76. 2013
    ..Biological targeted therapies might prove to be effective treatments of this condition...
  15. doi Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas 75235, USA
    Arthritis Rheum 58:1299-309. 2008
    ..The aim of this multicenter, randomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment...
  16. ncbi Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis
    Zheni Stavre
    Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, 55 Lake Ave North, Worcester, MA, 01655, USA
    Curr Rheumatol Rep 18:72. 2016
    ..We review the pathways, cytokines, and concepts important to the pathogenesis of bone resorption and formation in rheumatoid arthritis (RA) and spondyloarthritis (SpA)...
  17. pmc Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation
    Christian Schmidt-Lauber
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Ann Rheum Dis 74:2062-9. 2015
    ....